Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits.
The efficacy of cilofungin (LY121019) for aortic valve endocarditis caused by Candida albicans in rabbits was studied. Vegetation titers were similar for cilofungin-treated and untreated rabbits. No rabbit survived beyond 5 days in either group. All rabbits given amphotericin B survived, and titers were reduced. Cilofungin was ineffective in this model.
Padula
A
A
Medical Service, San Francisco General Hospital, California.
Chambers
H F
HF
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001021:Aortic Valve; D002176:Candida albicans; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D054714:Echinocandins; D004696:Endocarditis / Q000188:drug therapy* / Q000382:microbiology; D006207:Half-Life; D006349:Heart Valve Diseases / Q000188:drug therapy / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000627:therapeutic use; D010456:Peptides, Cyclic; D011817:Rabbits
D000935:Antifungal Agents; D054714:Echinocandins; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; C042101:cilofungin